FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095323841> ?p ?o ?g. }

• W3095323841 abstract "Abstract Background To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). Methods RANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC. Ramucirumab (10 mg/kg) plus docetaxel (75 mg/m 2 ) or placebo plus docetaxel were administered every 21 days until disease progression or unacceptable toxicity. Patients received maximum 10 cycles of docetaxel. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EuroQoL five-dimensions (EQ-5D-5L) were administered at baseline, start of each cycle, and 30-day follow-up visit. A ≥ 10-point change in QLQ-C30 scores was considered meaningful. Rates of improved/stable scores were compared between treatment arms using Fisher’s exact test. Time to deterioration (TtD) was estimated and compared using Kaplan–Meier estimation and log-rank test. Results Of the 530 patients, ~ 97% patients in each arm provided baseline QLQ-C30 data. On-treatment compliance was ≥ 88% for first 8 cycles. Mean baseline QLQ-C30 scores were similar between arms, with global quality of life (QoL), fatigue, pain, and insomnia having greatest impairment. Postbaseline rates of improved/stable QLQ-C30 scores were similar between treatment arms except for greater improvement in pain score with ramucirumab. TtD of QLQ-C30 scales favored ramucirumab arm. Baseline EQ-5D-5L index and visual analogue scale scores were similar between arms, followed by relatively stable on-treatment scores. EQ-5D-5L scores worsened at post-discontinuation follow-up visit. Conclusions Ramucirumab plus docetaxel did not negatively impact QoL compared with docetaxel alone in platinum-refractory aUC. Improved TtD and tumor associated rates of pain favored ramucirumab treatment. Clinical trail registration NCT02426125. https://clinicaltrials.gov/ct2/show/NCT02426125 . Date of registration: April 24th 2015" @default.
• W3095323841 created "2020-11-09" @default.
• W3095323841 creator A5007312682 @default.
• W3095323841 creator A5014625956 @default.
• W3095323841 creator A5025309761 @default.
• W3095323841 creator A5041610986 @default.
• W3095323841 creator A5049657362 @default.
• W3095323841 creator A5050042851 @default.
• W3095323841 creator A5063838757 @default.
• W3095323841 creator A5071199136 @default.
• W3095323841 creator A5071455815 @default.
• W3095323841 creator A5072911394 @default.
• W3095323841 creator A5083331837 @default.
• W3095323841 date "2020-11-07" @default.
• W3095323841 modified "2023-10-11" @default.
• W3095323841 title "Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)" @default.
• W3095323841 cites W1830813972 @default.
• W3095323841 cites W1834390835 @default.
• W3095323841 cites W1947168884 @default.
• W3095323841 cites W1966023125 @default.
• W3095323841 cites W1967841898 @default.
• W3095323841 cites W1990166011 @default.
• W3095323841 cites W2019607817 @default.
• W3095323841 cites W2046305550 @default.
• W3095323841 cites W2063202257 @default.
• W3095323841 cites W2080265313 @default.
• W3095323841 cites W2127577009 @default.
• W3095323841 cites W2167571044 @default.
• W3095323841 cites W2195040438 @default.
• W3095323841 cites W2300039540 @default.
• W3095323841 cites W2343426002 @default.
• W3095323841 cites W2602463982 @default.
• W3095323841 cites W2617848354 @default.
• W3095323841 cites W2620925856 @default.
• W3095323841 cites W2755607580 @default.
• W3095323841 cites W2777192533 @default.
• W3095323841 cites W2794976313 @default.
• W3095323841 cites W2800146731 @default.
• W3095323841 cites W2808069326 @default.
• W3095323841 cites W2896015079 @default.
• W3095323841 cites W2903794284 @default.
• W3095323841 cites W2905425294 @default.
• W3095323841 cites W2912440854 @default.
• W3095323841 cites W2936836027 @default.
• W3095323841 cites W2964014383 @default.
• W3095323841 cites W2966500633 @default.
• W3095323841 cites W2982865643 @default.
• W3095323841 cites W3010063926 @default.
• W3095323841 cites W3033340144 @default.
• W3095323841 cites W4250968058 @default.
• W3095323841 doi "https://doi.org/10.1186/s12894-020-00752-w" @default.
• W3095323841 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7648381" @default.
• W3095323841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33160359" @default.
• W3095323841 hasPublicationYear "2020" @default.
• W3095323841 type Work @default.
• W3095323841 sameAs 3095323841 @default.
• W3095323841 citedByCount "4" @default.
• W3095323841 countsByYear W30953238412022 @default.
• W3095323841 countsByYear W30953238412023 @default.
• W3095323841 crossrefType "journal-article" @default.
• W3095323841 hasAuthorship W3095323841A5007312682 @default.
• W3095323841 hasAuthorship W3095323841A5014625956 @default.
• W3095323841 hasAuthorship W3095323841A5025309761 @default.
• W3095323841 hasAuthorship W3095323841A5041610986 @default.
• W3095323841 hasAuthorship W3095323841A5049657362 @default.
• W3095323841 hasAuthorship W3095323841A5050042851 @default.
• W3095323841 hasAuthorship W3095323841A5063838757 @default.
• W3095323841 hasAuthorship W3095323841A5071199136 @default.
• W3095323841 hasAuthorship W3095323841A5071455815 @default.
• W3095323841 hasAuthorship W3095323841A5072911394 @default.
• W3095323841 hasAuthorship W3095323841A5083331837 @default.
• W3095323841 hasBestOaLocation W30953238411 @default.
• W3095323841 hasConcept C121608353 @default.
• W3095323841 hasConcept C126322002 @default.
• W3095323841 hasConcept C142724271 @default.
• W3095323841 hasConcept C143998085 @default.
• W3095323841 hasConcept C159110408 @default.
• W3095323841 hasConcept C168563851 @default.
• W3095323841 hasConcept C203092338 @default.
• W3095323841 hasConcept C204787440 @default.
• W3095323841 hasConcept C27081682 @default.
• W3095323841 hasConcept C2779551604 @default.
• W3095323841 hasConcept C2779951463 @default.
• W3095323841 hasConcept C2781190966 @default.
• W3095323841 hasConcept C71924100 @default.
• W3095323841 hasConceptScore W3095323841C121608353 @default.
• W3095323841 hasConceptScore W3095323841C126322002 @default.
• W3095323841 hasConceptScore W3095323841C142724271 @default.
• W3095323841 hasConceptScore W3095323841C143998085 @default.
• W3095323841 hasConceptScore W3095323841C159110408 @default.
• W3095323841 hasConceptScore W3095323841C168563851 @default.
• W3095323841 hasConceptScore W3095323841C203092338 @default.
• W3095323841 hasConceptScore W3095323841C204787440 @default.
• W3095323841 hasConceptScore W3095323841C27081682 @default.
• W3095323841 hasConceptScore W3095323841C2779551604 @default.
• W3095323841 hasConceptScore W3095323841C2779951463 @default.
• W3095323841 hasConceptScore W3095323841C2781190966 @default.
• W3095323841 hasConceptScore W3095323841C71924100 @default.
• W3095323841 hasFunder F4320307758 @default.
• W3095323841 hasIssue "1" @default.

• next